M

Merck

Makes medicines, vaccines and animal treatments

Technology Partnership Specialist

Full-TimeUpdated on 10/23/2026Deadline 12/31/26
No salary listed
Mid
Bachelor's
Singapore
Hybrid
IT OperationsIT Service Desk & End User Support

About the job

Requirements
  • A university degree in Computer Science, Information Systems, Engineering, or an equivalent field is desired.
  • At least 4 years of experience supporting IT operations, including at least 2 years of hands-on experience with Microsoft Windows desktops, Microsoft 365, Office Suite, and network printer support.
  • Practical exposure to audiovisual support, including video conferencing endpoints or Teams Rooms, displays, projectors, and audio setup and troubleshooting.
  • Working knowledge of IT service delivery and support processes, such as ITIL incident, request, and problem management.
  • Basic understanding of IT telecom room and structured cabling practices.
  • Ability to execute assignments with general direction and appropriate supervision.
  • Analytical and problem-solving ability, including knowing when to escalate.
  • Willingness to learn the company's infrastructure technology standards, IT strategy, and operating model.
  • Flexibility to provide occasional after-hours or weekend support for events, refreshes, and site activities.
  • Required skills include benefits management, business analysis, business process improvements, end user support, end-user training, escalation management, governance management, information technology, ITIL framework, IT service delivery, knowledge management, knowledge management systems, logical thinking, meeting facilitation, operations support, program management, service delivery, service operations, service request management, stakeholder relationship management, strategic planning, technical evaluation, technical support, and troubleshooting.
Responsibilities
  • Provide hands-on support for meeting-room and conference-room audiovisual systems, including Microsoft Teams Rooms, video conference endpoints, displays, projectors, cameras, microphones, speakers, control panels, and cabling.
  • Set up, test, and support hybrid and in-person events, town halls, and leadership meetings, including pre-event checks, rehearsal support, and on-site standby.
  • Perform routine audiovisual health checks, firmware and software updates, and preventive maintenance in coordination with vendors and global audiovisual product teams.
  • Troubleshoot audiovisual faults, coordinate repairs and replacements with vendors, and keep audiovisual equipment reflected in asset records.
  • Coach users on meeting-room technology and maintain quick-reference guides to reduce repeat issues.
  • Serve as the IT point of contact for site executives and senior leaders, providing responsive, discreet support for their devices, mobile technology, collaboration tools, and home or remote setups.
  • Prepare and support executive meetings, town halls, board and leadership sessions end to end, including room and audiovisual readiness, pre-meeting technology checks, presenter setup, rehearsal support, and on-site standby.
  • Support executive travel and visiting leadership, including pre-travel device checks, loaner equipment, connectivity in other locations, and readiness for offsite or customer-facing events.
  • Prioritize and follow through on executive requests and incidents, coordinating with global, regional, and platform teams to shorten resolution time and keeping the executive and their assistant informed of progress.
  • Build working relationships with executive assistants to anticipate technology needs ahead of key meetings, site visits, and business events.
  • Handle confidential information and executive systems in accordance with company security, privacy, and data-handling policies.
  • Provide day-to-day IT end-user support for Singapore, including consultation on technology use and adoption.
  • Log, track, and resolve IT requests and incidents within agreed service levels, escalate complex problems, and keep users informed of impact.
  • Support IT onboarding and offboarding across the employee journey.
  • Educate users and encourage use of global standard procedures for IT service requests and incident tickets.
  • Monitor end-user client IT computing infrastructure and escalate anomalies affecting availability or stability.
  • Work with global and regional support teams on IT initiatives implemented in country.
  • Participate in assigned IT projects and deliver defined tasks to agreed timelines.
  • Engage support and company IT platform teams when requests or incidents exceed the local country IT team's ability to resolve them.
  • Work with IT colleagues in JCAP as One IT Team.
  • Support business initiatives using the company's standard IT technology.
  • Document fixes and update knowledge articles.
  • Follow IT asset management processes and keep asset records complete and up to date.
  • Support IT equipment lifecycle refreshes, including scheduling, deployment, data wiping, and disposal record keeping.
  • Work alongside IT contractors on daily service delivery, check that requests and incidents are handled according to service-level agreements, and raise quality or performance concerns to senior team members.
  • Follow the company's procurement process for IT goods and services with guidance from senior team members.
  • Ensure compliance with safety and security protocols for IT equipment handling and storage.
  • Analyze, evaluate, and diagnose complex specialist technical problems in a timely manner.
  • Act as a technical consultant to IT teams, management, users, and vendors on service requests, utilization, standards, security, and other specialist technical matters.
  • Implement new technologies and procedures, deliver integration and configuration work, and respond to complex problems.
  • Deliver services in line with the IT strategy and product model.
  • Ensure staff have the information, equipment, and tools needed to complete projects, and manage their activities.
  • Manage suppliers to meet key performance indicators and agreed targets.
  • Manage operational relationships between suppliers and raise and resolve potential disputes or conflicts.
  • Represent the Global End User Services organization at the sites.
  • Coach, counsel, and build teams.
  • Summarize issues and prepare presentations for senior IT leadership.
Desired Qualifications
  • Exposure to manufacturing or lab operations support.
  • Basic LAN and WLAN networking knowledge.
  • Experience coordinating with IT vendors or contractors.
  • Certifications such as CompTIA A+, ITIL Foundation, or Microsoft 365 or Teams Rooms credentials.
  • Experience supporting multiple sites or a regional user base.

About the company

Merck develops prescription medicines, vaccines and veterinary treatments for patients, health systems and animal owners worldwide. Its vaccine portfolio includes Gardasil 9, which helps prevent cancers and other diseases caused by several types of human papillomavirus. The company takes potential treatments through laboratory research and clinical trials, then manufactures and sells approved products to drug distributors, hospitals, physicians and governments. Its animal health division sells medicines and vaccines to veterinarians, farmers and pet owners, while selected drug partnerships also earn shared profits or royalties. Founded in 1891, Merck is headquartered in Rahway, New Jersey.

Company Size

10,001+

Company Stage

IPO

Headquarters

Rahway, New Jersey

Founded

1891

Get referred to Merck

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • U.S. employees build retirement benefits: Merck pairs a defined benefit pension with a matching 401(k).
  • Scientists work within a large research network: Merck reports approximately 24,700 employees in R&D.
  • Animal health adds growth: August 2026 results report Q2 sales of $1.8 billion, up 8% year over year.

What critics are saying

  • Job security faces cuts: Merck's active restructuring program eliminates roles and shrinks its global real estate footprint.
  • Keytruda protection narrows: its main U.S. patent expires in 2028, with additional patents expiring in 2029.
  • Revenue is concentrated: August 2026 results show Keytruda products generated $8.4 billion of Merck's $16.6 billion Q2 sales.

What makes Merck unique

  • Merck extends into farm technology: SenseHub continuously monitors livestock for behavioral and physiological changes.
  • Merck publishes open medical knowledge: its Manuals give clinicians and patients free online references.
  • Merck's donation commitment is open-ended: Mectizan supplies for river blindness continue for as long as needed.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

-19%

1 year growth

-20%

2 year growth

-20%
Yahoo Finance
Oct 22nd, 2026
Moderna sinks 18% after leak of melanoma vaccine data showing 42% lower recurrence risk

Moderna shares fell 18% after detailed Phase 3 results for its personalised melanoma vaccine, developed with Merck, appeared online two days before their scheduled presentation. The data surfaced on medical news site Oncology Central and was taken down shortly afterwards. Trading in Moderna was halted for volatility. The leaked data still looks positive. Adding the vaccine, intismeran autogene, to Merck's Keytruda cut the risk of recurrence or death by 42% versus Keytruda alone. After two years, 82.2% of patients on the combination were alive and cancer-free, against 70% on Keytruda alone. The trial enrolled 1,137 patients. The stock had risen more than eightfold this year, and traded at about 52x forward sales before the drop. The 42% figure also trails the 49% from the smaller Phase 2b trial. Full results are due at the ESMO Congress on Saturday.

Yahoo Finance
Oct 22nd, 2026
Pfizer's 5.7% yield signals risk: dividends took 108% of free cash flow vs Merck's 66%

Merck's dividend looks safer than Pfizer's, despite Pfizer's higher yield, according to a 24/7 Wall St. comparison. Pfizer yields about 5.7% against Merck's 2.2%. In 2025, Pfizer's dividends used 108% of free cash flow, while Merck's used 66%. In the first half of 2026, Merck's free cash flow covered 174% of its payout; Pfizer's covered about 51%. Merck has raised its quarterly dividend 39% since 2020, to $0.85. Pfizer's rose 13% and has been flat at $0.43 since January 2025. Pfizer is cheaper, at about 10 times 2026 earnings against Merck's 17. Pfizer targets a return to growth from 2029, while Merck's newer drugs are already selling.

Yahoo Finance
Oct 21st, 2026
Keytruda is half of Merck's $16.6B quarterly sales, so what if growth stalls?

Merck's Keytruda cancer drug family generated $8.4 billion in fiscal Q2 2026, about half of the company's $16.6 billion revenue. Excluding currency, Keytruda sales grew 4%, the same pace as total revenue. Management said on the August 4 call that US Keytruda growth will moderate as the drug reaches peak penetration. A Dutch court has also barred Merck from selling subcutaneous Keytruda in eight European markets, Barron's reported. Newer drugs are growing faster. WINREVAIR sales rose 75% to $588 million, and WELIREG sales rose 67%. Free cash flow of $16.1 billion covered dividends of $8.3 billion about twice. Total debt rose to $53.9 billion from $35.4 billion a year earlier. Merck is expected to report results on October 29.

Citybiz
Oct 20th, 2026
Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors.

Epicrispr Biotechnologies appoints Enoch Kariuki to Board of Directors. October 20, 2026 Enoch Kariuki Epicrispr Biotechnologies, a clinical-stage biotechnology company developing epigenetic therapies, has appointed Enoch Kariuki, PharmD, to its Board of Directors as the company advances its lead treatment candidate, EPI-321, toward pivotal clinical development and expands its pipeline of gene-modulating medicines. Kariuki brings extensive experience in biotechnology operations, corporate strategy, capital markets and business development. Throughout his career, he has participated in more than $10 billion in strategic financings and mergers and acquisitions across the life sciences industry. His appointment strengthens Epicrispr's board as the company works to advance its clinical programs, evaluate development priorities and establish the financial and operational infrastructure needed to support future growth. "Enoch is an accomplished biotechnology leader with a proven track record of building and scaling companies, guiding programs through pivotal clinical and regulatory milestones, and executing strategic transactions that create lasting value," said Amber Salzman, Ph.D., CEO of Epicrispr Biotechnologies. Salzman said Kariuki's combination of operational, financial and strategic experience will support the company's efforts to advance EPI-321 and develop additional epigenetic medicines. Kariuki currently serves as President of Endeavor BioMedicines, where he oversees corporate strategy and operations. His responsibilities include guiding organizational development and supporting the company's business and clinical development objectives. Previously, he served as CEO of Lengo Therapeutics, a biotechnology company acquired by Blueprint Medicines. He also held the position of Chief Financial Officer at VelosBio, which was acquired by Merck. Earlier in his career, Kariuki was Senior Vice President of Corporate Development at Synthorx, where he led the company's initial public offering and played a significant role in its subsequent acquisition by Sanofi. His experience also includes investment and advisory positions at H.I.G. Capital, Leerink Partners and UBS Investment Bank, providing a background in financing, strategic transactions and biotechnology investment analysis. These roles have given Kariuki experience across multiple stages of biotechnology company development, from securing financing and establishing corporate strategy to executing acquisitions and supporting clinical-stage growth. At Epicrispr, that experience will be relevant as the company evaluates the resources, partnerships and development strategies required to advance its therapeutic programs. Epicrispr's lead candidate, EPI-321, is being evaluated in clinical trials for facioscapulohumeral muscular dystrophy (FSHD), a genetic neuromuscular disease characterized by progressive muscle weakness. The company is developing EPI-321 using its proprietary Gene Expression Modulation System (GEMS), an epigenetic technology platform designed to regulate gene expression without directly changing the underlying DNA sequence. Epigenetic therapies seek to influence how genes are activated or suppressed. Epicrispr's approach is intended to provide precise and durable modulation of gene activity, potentially addressing diseases associated with abnormal gene expression. The company is initially concentrating on neuromuscular disorders while developing additional gene-modulating treatments for other conditions. Advancing EPI-321 toward pivotal development represents an important operational priority. Clinical-stage biotechnology companies approaching later-stage trials must address study design, regulatory engagement, manufacturing readiness, financing requirements and long-term commercialization planning. Board members with experience in clinical development and capital markets can provide oversight as management evaluates those requirements and determines how to allocate resources across its pipeline. "Epicrispr is at an exciting inflection point, with compelling early clinical data supporting the potential of its differentiated epigenetic platform to address diseases with significant unmet medical needs," Kariuki said. He identified EPI-321's development in FSHD and the company's broader epigenetic technology platform as areas of opportunity, while emphasizing his intention to support Epicrispr's strategic priorities. In addition to his executive responsibilities, Kariuki serves on the boards of Zentalis Pharmaceuticals and Pheon Therapeutics, chairing the audit committees at both companies. He previously served on the boards of Imago Biosciences and ProfoundBio, which were acquired by Merck and Genmab, respectively. His board experience includes financial oversight and corporate governance responsibilities relevant to biotechnology companies operating in capital-intensive research and development environments. Kariuki earned a Doctor of Pharmacy degree from Texas Southern University and an MBA from the Tuck School of Business at Dartmouth College. He also completed a postdoctoral fellowship in research and development strategy and analytics at Bristol Myers Squibb. Epicrispr continues to advance EPI-321 through clinical development while expanding its portfolio of gene-modulating therapies. Kariuki's appointment adds biotechnology financing, transaction and operational experience to the board as the company prepares for its next stage of clinical development and evaluates opportunities to advance its epigenetic medicines platform.

Ash
Oct 20th, 2026
Ash announces $10M Series A funding to uplevel at-home health testing to close healthcare gaps for millions

Ash secures $10M Series A funding led by Merck GHI Fund. We are scaling at home lab test programs to close care gaps and bring patients into the care cycle.